Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Open Access | 10.1172/JCI213400

Corrigendum to Markers of compromised gut epithelial barrier integrity increase during the menopause transition

Albert Shieh, Marta Epeldegui, Arun S. Karlamangla, Rheinallt Jones, Roberto Pacifici, and Gail A. Greendale

Find articles by Shieh, A. in: PubMed | Google Scholar

Find articles by Epeldegui, M. in: PubMed | Google Scholar |

Find articles by Karlamangla, A. in: PubMed | Google Scholar |

Find articles by Jones, R. in: PubMed | Google Scholar |

Find articles by Pacifici, R. in: PubMed | Google Scholar |

Find articles by Greendale, G. in: PubMed | Google Scholar

Published November 2, 2026 - More info

Published in Volume 136, Issue 21 on November 2, 2026
J Clin Invest. 2026;136(21):e213400. https://doi.org/10.1172/JCI213400.
© 2026 Shieh et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 2, 2026 - Version history
View PDF

Related article:

Markers of compromised gut epithelial barrier integrity increase during the menopause transition
Albert Shieh, Marta Epeldegui, Arun S. Karlamangla, Rheinallt Jones, Roberto Pacifici, Gail A. Greendale
Albert Shieh, Marta Epeldegui, Arun S. Karlamangla, Rheinallt Jones, Roberto Pacifici, Gail A. Greendale
The study demonstrates that gut epithelilal damage and activation of the immune system increase rapidly during the menopause transition.
Clinical Research and Public Health Endocrinology Inflammation Reproductive biology

Markers of compromised gut epithelial barrier integrity increase during the menopause transition

  • Text
  • PDF
Abstract

BACKGROUND In female murine models, one source of inflammation is a menopause-related increase in gut permeability. We examined whether the menopause transition (MT) in women is associated with an increase in markers of gut epithelial dysfunction and gut microbial product translocation, signals of compromised gut epithelial barrier integrity.METHODS In 964 women, we measured markers of gut epithelial dysfunction (fatty acid binding protein 2, FABP2) and gut microbial antigen translocation (soluble CD14, sCD14) using sera collected before, during, and after the MT. Multivariable mixed effects regressions fit piecewise linear models to repeated FABP2 or sCD14 measures relative to time from final menstrual period (FMP). Covariates were age at FMP, race and ethnicity, and BMI.RESULTS FABP2 and sCD14 did not change significantly until 2.5 years pre-FMP. At that point, FABP2 began rising; sCD14 began increasing 6 months later. FABP2 and sCD14 peaked 6 and 6.5 years after FMP, respectively; subsequent levels remained stable. During the ~9-year interval of MT-related gain in gut barrier compromise markers, annual FABP2 and sCD14 increases were 2.6% (95% CI: 1.7% to 3.4%) and 0.8% (95% CI: 0.6% to 1.1%), respectively, among White women with sample-average BMI and age at FMP. FABP2 and sCD14 change rates did not differ significantly by race and ethnicity, BMI, or age at FMP.CONCLUSION The MT is associated with a rise in markers of compromised gut barrier integrity, suggesting that this pathway of inflammation, previously described in animal models, occurs in humans.FUNDING NIH U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495, U19AG063720, 5R01AR081794, R01AR075729.

Authors

Albert Shieh, Marta Epeldegui, Arun S. Karlamangla, Rheinallt Jones, Roberto Pacifici, Gail A. Greendale

×

Original citation: J Clin Invest. 2026;136(17):e205059. https://doi.org/10.1172/JCI205059.

Citation for this corrigendum: J Clin Invest. 2026;136(21):e213400. https://doi.org/10.1172/JCI213400.

The results section has been updated to correct the upper limit of the confidence interval for the annual reported increase for FABP2. The correct text appears below.

During its period of MT-related increase (FMP –2.5 to FMP +6 years), FABP2 rose by 2.6% per year (95% CI 1.7 to 3.4%; P < 0.0001).

The HTML and PDF versions of the text have been updated online.

The authors regret the error.

Footnotes

See the related article at Markers of compromised gut epithelial barrier integrity increase during the menopause transition.

Version history
  • Version 1 (November 2, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts